摘要
目的:比较恩替卡韦和拉夫米定治疗乙肝的疗效,寻求更好的乙肝治疗方法。方法:将我院入住的乙肝患者60例纳入研究对象之中,按照随机原则将患者分为恩替卡韦组和拉夫米定组。拉夫米定治疗组患者在此基础上予以拉夫米定口服治疗,恩替卡韦治疗组患者在此基础上予以恩替卡韦口服治疗,比较两组患者治疗16周、32周、64周后的ALT恢复正常、抗肝纤维化指标恢复情况和Child-Pugh肝功能评分分级情况,使用spss15.0统计软件对以上数据进行分析,综合评定两组患者的治疗效果。结果:两组患者治疗16周、32周、64周后,肝功能各指标较治疗前得到明显的改善,但恩替卡韦组的肝功能改善情况显著优于拉夫米定组,经SPSS15.0软件分析后χ2检验值分别为10.76、9.93、5.96,P值均<0.05,二者治疗的临床差别在统计学上均具有意义。结论:恩替卡韦治疗乙肝的疗效显著优于拉夫米定。
Objective：Comparing the curative effects of treating hepatitis B by using lamivudine and entecavir respectively,in order to find out the better way of treating hepatitis B.Methods：Choosing 60 of those hepatitis B patients who being treated at our hospital right now as study objects,and divided them into entecavir group and lamivudine group randomly.Giving lamivudine peroral treatment to those who in lamivudine group,while giving entecavir peroral treatment to those who in entecavir group,then compare their ALT recovery situations,resistance to index of liver fibrosis recovery conditions and Child-Pugh liver function rating situations respectively after 16 weeks,32 weeks and 64 weeks.Using spss15.0 statistical software to analyse the above statistic and make an overall evaluation to the efficacy of these two groups.Results：After received the treatment 16 weeks,32 weeks and 64 weeks later,the two groups patients’ kinds of liver function index has improved obviously compared with before,but the liver function improvement situation in entecavir group is significantly better than lamivudine group,after the analysis of SPSS15.0 software,the test value of χ2is 10.76,9.93,5.96 respectively,P0.05.The different clinical effects of these two groups are meaningful to statistics.Conclusion：Using entecavir to treat hepatitis B can have an obviously better efficacy than using lamivudine.
出处
《中国医药导刊》
2013年第1期112-113,共2页
Chinese Journal of Medicinal Guide
